SynthesisJournal of neurology2025
Risk of intracerebral haemorrhage with tenecteplase versus alteplase in acute ischaemic stroke: a meta-analysis.
Synthesis in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world analysis of fibrinolytics-associated bleeding and literature synthesis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ultrasound-Mediated Thrombolysis: From Mechanistic Insights to Advanced Nanoplatforms and Clinical Translation.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTenecteplase (TNK) has been widely used in thrombolytic therapy for acute ischaemic stroke (AIS), but TNK-related intracranial haemorrhage(ICH) remains a severe complication. However, few data are available to guide the management of tenecteplase-related intracranial haemorrhage. The objective of this study was to evaluate the risk of intracranial haemorrhage associated with tenecteplase compared with alteplase in patients with acute ischaemic stroke.
methodsA thorough literature search of Embase, PubMed, Cochrane Library, and Web of Science was conducted for randomized controlled trials (RCTs) published up to October 2024. Randomized controlled trials (RCTs) investigating the risk of intracranial haemorrhage between tenecteplase and alteplase (ALT) were eligible for inclusion. To reduce study bias, we uniformly adopted the random-effects model for the meta-analysis of all haemorrhagic outcomes.
resultsEleven RCTs with a total of 7466 patients were analysed in this meta-analysis. No significant differences were observed between TNK-treated patients and ALT-treated patients in overall ICH (13.22% vs 12.72%; RR = 1.02, 95% CI = 0.8-1.24; p = 0.81), symptomatic ICH (3.09% vs. 2.49%; RR = 1.21, 95% CI = 0.92-1.59; p = 0.18), and asymptomatic ICH (8.68% vs. 9.03%; RR = 0.95, 95% CI = 0.78-1.16; p = 0.62). Subgroup analyses based on TNK dosage (0.25 mg/kg vs. 0.4 mg/kg) compared to ALT showed no significant differences in ICH incidences. The proportions of ICH in different locations, including intraventricular hemorrhage, subarachnoid hemorrhage, hemorrhagic infarction, parenchymal hematoma, and remote parenchymal hematoma, were also similar between the TNK and ALT groups (all P > 0.05).
conclusionOur study provides the best evidence to date that TNK has a similar risk of ICH to ALT in AIS, with a very low incidence of symptomatic ICH, supporting that TNK has a good safety profile in terms of ICH.
Indexed as
Identifiers
40208343What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.